JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: Results from a Phase 2 randomized controlled clinical trial

Nephrology Dialysis Transplantation

Volumn 33, Issue 11, 2018, Pages 1950-1959

  Tuttle, Katherine R ^a,b   Brosius, Frank C ^c,d   Adler, Sharon G ^e   Kretzler, Matthias ^c   Mehta, Ravindra L ^f   Tumlin, James A ^g   Tanaka, Yoshiya ^h   Haneda, Masakazu ⁱ   Liu, Jiajun ^j   Silk, Maria E ^j   Cardillo, Tracy E ^j   Duffin, Kevin L ^j   Haas, Joseph V ^j   Macias, William L ^j   Nunes, Fabio P ^j   Janes, Jonathan M ^j  

^a Providence Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e UCLA MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

ⁱ ASAHIKAWA MEDICAL COLLEGE   (Japan)

^j ELI LILLY AND COMPANY   (United States)

more..

Author keywords

albuminuria; biomarkers; diabetic nephropathy; estimated glomerular filtration rate; JAK inhibition

Indexed keywords

AMYLOID A PROTEIN; BARICITINIB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; JANUS KINASE 1; JANUS KINASE 2; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; AZETIDINE DERIVATIVE; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; AFRICAN AMERICAN; ALBUMINURIA; ANEMIA; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INHIBITION; ENZYME INHIBITION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; COMPLICATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GLOMERULUS FILTRATION RATE; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS;

ALBUMINURIA; AZETIDINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLOMERULAR FILTRATION RATE; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; SULFONAMIDES;

EID: 85050914015     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfx377     Document Type: Article

References (59)

1. Saran R, Li Y, Robinson B et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 2015; 66 (Suppl 1): A7
2. Kramer A, Pippias M, Stel VS et al. Renal replacement therapy in Europe: A summary of the 2013 ERA-EDTA Registry Annual Report with a focus on diabetes mellitus. Clin Kidney J 2016; 9: 457-469
3. Tuttle KR, Bakris GL, Bilous RW et al. Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care 2014; 37: 2864-2883
4. de Boer IH, AfkarianM, Rue TC et al. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2014; 25: 2342-2350
5. ANZDATA Registry. 38th Report: Incidence of End Stage Kidney Disease. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry, 2016
6. Afkarian M, Sachs MC, Kestenbaum B et al. Kidney disease and increased mortality risk in type 2 diabetes. J AmSoc Nephrol 2013; 24: 302-308
7. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, 2014
8. Ritz E, Rychlik I, Locatelli F et al. End-stage renal failure in type 2 diabetes: Amedical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
9. Nwankwo E, Bello AK, El Nahas AM. Chronic kidney disease: stemming the global tide. Am J Kidney Dis 2005; 45: 201-208
10. Szczech LA, Lazar IL. Projecting the United States ESRD population: issues regarding treatment of patients with ESRD. Kidney Int Suppl 2004; 90: S3-S7
11. Atkins RC. The epidemiology of chronic kidney disease. Kidney Int Suppl 2005; 94: S14-S18
12. McClellan WM. Epidemiology and risk factors for chronic kidney disease. Med Clin North Am 2005; 89: 419-445
13. de Boer IH. Chronic kidney disease-A challenge for all ages. JAMA 2012; 308: 2401-2402
14. U.S. Renal Data System. USRDS 2014 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2014
15. Brenner BM, CooperME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl JMed 2001; 345: 861-869
16. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.NEngl JMed 2001; 345: 851-860
17. Thomas MC, Groop PH. New approaches to the treatment of nephropathy in diabetes. Expert Opin Investig Drugs 2011; 20: 1057-1071
18. Abdel-Rahman EM, Saadulla L, Reeves WB et al. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med 2012; 27: 458-468
19. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEngl JMed 2017; 377: 644-657
20. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322
21. Mann JFE, Orsted DD, Brown-Frandsen K et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839-848
22. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. NEngl JMed 2016; 375: 1834-1844
23. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, andmortality in type 2 diabetes.NEngl JMed 2015; 373: 2117-2128
24. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
25. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci 2013; 124: 139-152
26. OShea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012; 36: 542-550
27. Berthier CC, Zhang H, Schin M et al. Enhanced expression of Janus kinasesignal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009; 58: 469-477
28. Choudhury GG, Ghosh-Choudhury N, Abboud HE. Association and direct activation of signal transducer and activator of transcription1alpha by platelet-derived growth factor receptor. J Clin Invest 1998; 101: 2751-2760
29. Woroniecka KI, Park AS, Mohtat D et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011; 60: 2354-2369
30. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7: 327-340
31. Brosius FC III, He JC. JAK inhibition and progressive kidney disease. Curr Opin Nephrol Hypertens 2015; 24: 88-95
32. Zhang H, Nair V, Saha J et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease inmice. Kidney Int 2017; 92: 909-921
33. Marrero MB, Banes-Berceli AK, Stern DM et al. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F762-F768
34. GenoveseMC, Kremer J, Zamani O et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl JMed 2016; 374: 1243-1252
35. Fleischmann R, Schiff M, van der Heijde D et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 2017; 69: 506-517
36. Dougados M, van der Heijde D, Chen YC et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results fromthe RA-BUILD study. Ann Rheum Dis 2017; 76: 88-95
37. Taylor PC, Keystone EC, van der Heijde D et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis.N Engl J Med 2017; 376: 652-662
38. Anderberg RJ, Meek RL, Hudkins KL et al. Serumamyloid A and inflammation in diabetic kidney disease and podocytes. Lab Invest 2015; 95: 250-262
39. de Zeeuw D, Bekker P, Henkel E et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: A randomised trial. Lancet Diabetes Endocrinol 2015; 3: 687-696
40. Vaidya VS, Niewczas MA, Ficociello LH et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-Acetyl-beta-Dglucosaminidase. Kidney Int 2011; 79: 464-470
41. Niewczas MA, Gohda T, Skupien J et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 2012; 23: 507-515
42. Gohda T, Niewczas MA, Ficociello LH et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 2012; 23: 516-524
43. Titan SM, Vieira JMJr, DominguezWV et al. Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy. J Diabetes Complications 2012; 26: 546-553
44. Wolkow PP, Niewczas MA, Perkins B et al. Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics. J AmSoc Nephrol 2008; 19: 789-797
45. Pichler R, Afkarian M, Dieter BP et al. Immunity and inflammation in diabetic kidney disease: Translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol 2017; 312: F716-F731
46. Menne J, Eulberg D, Beyer D et al. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant 2016; 32: 1-9
47. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553
48. Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213
49. Fried LF, Emanuele N, Zhang JH et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369: 1892-1903
50. Mann JF, Green D, Jamerson K et al. Avosentan for overt diabetic nephropathy. J AmSocNephrol 2010; 21: 527-535
51. Phillips CO, Kashani A, Ko DK et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials. Arch InternMed 2007; 167: 1930-1936
52. Papp KA, Menter MA, RamanMet al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-To-severe psoriasis. Br J Dermatol 2016; 174: 1266-1276
53. Khoshdel A, Carney S, Gillies A et al. Potential roles of erythropoietin in the management of anaemia and other complications diabetes. Diabetes Obes Metab 2008; 10: 1-9
54. Parganas E, Wang D, Stravopodis D et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385-395
55. Kremer JM, Emery P, Camp HS et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-Tumor necrosis factor therapy. Arthritis Rheumatol 2016; 68: 2867-2877
56. Schwartz DM, Kanno Y, Villarino A et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017; 16: 843-862
57. Taylor PC, Abdul Azeez M, Kiriakidis S. Filgotinib for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 2017; 26: 1181-1187
58. Payne C, Zhang X, Shahri N et al. Evaluation of potential drug-drug interactions with baricitinib. Ann Rheum Dis 2015; 74: 1063
59. AfkarianM, Zelnick LR, Hall YN et al. Clinicalmanifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 2016; 316: 602-610